FDA warned Cetylite Industries over CGMP violations at its Pennsauken, NJ facility, including unvalidated testing and inadequate OOS investigations for topical anesthetics.
What happened
FDA inspected the facility from September 20 to September 24, 2021. FDA found the company used an aerosol-form United States Pharmacopeia (USP) method to test its gel topical anesthetic and used an alternative method without validating it as equivalent or better than the USP method. FDA also found the company failed to adequately investigate out-of-specification (OOS) tetracaine HCl potency results of 114.7%, 115.2%, 118.9%, and 118.3% and released the lot after additional retests produced passing results.
What FDA found
The company failed to establish laboratory controls with scientifically sound and appropriate specifications, standards, sampling plans, and test procedures to assure drug products conform to appropriate standards.
21 CFR 211.160(b)The company tested its gel product using a method for the aerosol form and an unvalidated alternative method without demonstrating equivalence to the USP method.
21 CFR 211.160(b)The company failed to thoroughly investigate unexplained out-of-specification tetracaine HCl potency results and released the lot after retesting with other methods produced passing results without adequate scientific justification.
21 CFR 211.192
What FDA wants
FDA tells Cetylite to respond in writing within 15 working days describing what it has done to correct the violations and prevent recurrence. FDA also asks for a commitment to current USP methods until alternatives are proven equivalent or better, a comprehensive method-equivalence study, retesting of reserve samples, and an action plan for product quality or patient safety risks in U.S. distribution, including possible customer notifications, recalls, or market withdrawals.
Who should pay attention
- pharmacies and clinicians using Cetacaine topical anesthetics
- distributors and brands selling Cetylite drug products
- quality teams at drug manufacturers and testing labs using USP methods
This is a summary. Read the original letter on fda.gov.